Aptamer-based applications for cardiovascular disease

• Published in: Frontiers in bioengineering and biotechnology 2022-10, Vol.10, p.1002285-1002285
• Main Authors: Chen, Xinyuan, Ma, Yue, Xie, Yuquan, Pu, Jun
• Format: Article
• Language: English
• Subjects: antithrombotic therapy; aptamer; atherosclerosis; Bioengineering and Biotechnology; cardiovascular disease; precision medicine; von Willebrand factor
• ISSN: 2296-4185; 2296-4185
• DOI: 10.3389/fbioe.2022.1002285

Cardiovascular disease (especially atherosclerosis) is a major cause of death worldwide, and novel diagnostic tools and treatments for this disease are urgently needed. Aptamers are single-stranded oligonucleotides that specifically recognize and bind to the targets by forming unique structures in vivo , enabling them to rival antibodies in cardiac applications. Chemically synthesized aptamers can be readily modified in a site-specific way, so they have been engineered in the diagnosis of cardiac diseases and anti-thrombosis therapeutics. Von Willebrand Factor plays a unique role in the formation of thrombus, and as an aptamer targeting molecule, has shown initial success in antithrombotic treatment. A combination of von Willebrand Factor and nucleic acid aptamers can effectively inhibit the progression of blood clots, presenting a positive diagnosis and therapeutic effect, as well as laying a novel theory and strategy to improve biocompatibility paclitaxel drug balloon or implanted stent in the future. This review summarizes aptamer-based applications in cardiovascular disease, including biomarker discovery and future management strategy. Although relevant applications are relatively new, the significant advancements achieved have demonstrated that aptamers can be promising agents to realize the integration of diagnosis and therapy in cardiac research.